COMO – Combined Microorganisms against Cancer
COMO is Redbiotec’s powerful novel immune-oncology platform. We reinforce oncolytic viruses with bacteria. We apply COMO to existing oncolytic viruses increasing their potency. Additionally, and for the best match with bacteria, we also develop our own unique oncolytic viruses.
Fighting cancer stem cells
Redbiotec’s primary target are cancer stem cells (CSC) – a rare population of tumour-initiating cells that are capable of self-renewal and differentiation, and are present in many cancer types. In comparison to normal cancer cells, CSCs are less sensitive to conventional therapies (chemotherapy and radiotherapy) – their resistance might lead to more aggressive tumour recurrence. To date, many immuno- therapies are not able to target CSC mostly due to low T-cell killing efficacy. Tumour resection might lead to the recurrence as well, as CSC might reside in the invasive front of the tumour zone. Oncolytic Viruses have the potential to overcome these problems. With COMO approach, we aim at more efficient targeting of CSC at their all dedicated niches, deeper tumour penetration and more effective tumour cells eradication.
Overview Redbiotec’s COMO against cancer stem cells
- Targeting cancer stem cells (CSC) in their niches
- Using oncolytic viruses (OV)
- Using bacterial targeting and delivery of OV
- Supportive effect by bacteria targeting cancer relavant non-malignant cells
Redbiotec’s COMO platform also overcomes one of today’s key bottleneck of the manufacturing of oncolytiv viruses in sufficient titer for systemic administration.
Medical application – reduce cancer recurrences
Redbiotec is currently evaluating different medical applications. COMO has a big potential to become part of a first-line therapy as the removal of cancer stem cells is expected to significantly reduce the likelihood of cancer recurrences.